Database Member Home
RAS Member Home
Identifying different types of Key Opinion Leaders (KOLs), segmenting them according to their influence and developing appropriate relationships along a product’s lifecycle are important initial steps to successful KOL engagement. Therefore, biopharmaceutical companies must establish the right contact frequency for visits with Key Opinion Leaders and find ways to streamline multiple touch points with KOLs to curb internal competition for their attention.
This Best Practices, LLC video provides insights around the ideal contact frequency for National KOLs and Regional KOLs, and activities that drive KOL management. It provides the best practices and insights around successful KOL engagement.
Medical Affairs leaders can use these insights to develop strategic profiling and recruitment mechanisms to identify core targets, and segment KOLs by the traits required for their needs and strategy.
A must-have for all pharmaceutical, biotech and medical device manufacturing executives, this Best Practices' R&D Quality Assurance bundle tells you everything you need to know about quality... (ID OPS-95)
Read More »
Best Practices’ Market Research series highlights best practices in market research... (ID SMS-169)
Best Practices’ Pharma Thought Leadership series examines thought leadership in the context of patient advocacy while creating effective relationships and global product launches... (ID SMS-156)
The objective of this benchmarking study is to help biopharma leaders develop competitive launch and pre-launch activity budgets to ensure successful U... (ID PSM-326)
Pharmaceutical and biotech companies are increasingly under pressure to deliver effective new products in shorter time frames while minimizing development costs... (ID PSM-229)
The biopharmaceutical sector has seen dozens of new product launches in the last few years, including some notable new drugs targeting the oncology therapeutic area... (ID PSM-267)
The biopharmaceutical sector has seen dozens of new product launches in the last few years, including some notable new drugs targeting the metabolic therapeutic area... (ID PSM-266)
The biopharmaceutical sector has seen dozens of new product launches in the last few years, including some notable new drugs targeting the cardiovascular therapeutic area... (ID PSM-264)